A Phase 1, Open Label, Single Dose Study To Investigate The Pharmacokinetics, Safety and Tolerability Of Dalbavancin In Hospitalized Children Aged 3 Months to 11 Years Receiving Standard Intravenous Anti-Infective Treatment For Bacterial Infections

Trial Profile

A Phase 1, Open Label, Single Dose Study To Investigate The Pharmacokinetics, Safety and Tolerability Of Dalbavancin In Hospitalized Children Aged 3 Months to 11 Years Receiving Standard Intravenous Anti-Infective Treatment For Bacterial Infections

Completed
Phase of Trial: Phase I

Latest Information Update: 03 Jan 2017

At a glance

  • Drugs Dalbavancin (Primary)
  • Indications Bacterial infections
  • Focus Pharmacokinetics
  • Sponsors Durata Therapeutics
  • Most Recent Events

    • 03 Jan 2017 Results of pooled post hoc analysis of this trial and other trial (70033793) related to pharmacokinetic data were published in the Pediatric Infectious Disease Journal
    • 30 Oct 2016 Results assessing tolerability of Dalbavancin presented at the IDWeek 2016.
    • 22 Jun 2015 Status changed from recruiting to completed as reported by ClinicalTrials.gov
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top